Ipratropium Bromide
Locally administered (inhaled) ipratropium bromide is an antimuscarinic agent used for the adjunctive treatment of bronchospastic conditions, such as Recurrent Airway Obstruction (RAO) in horses and chronic respiratory diseases in small animals. **Clinical Pearls:** * Ipratropium is a quaternary ammonium derivative of atropine. Because of its highly polar nature, it is poorly absorbed into the systemic circulation and does not readily cross the blood-brain barrier, significantly reducing the risk of systemic anticholinergic side effects. * It has a relatively short duration of activity and may need to be administered frequently. * While there is limited formal pharmacokinetic data in small animals, it is generally considered safe and effective as an adjunctive bronchodilator.
Mechanism: Ipratropium acts as a competitive antagonist of **acetylcholine** at muscarinic receptors in the bronchial smooth muscle. * **Mechanism:** Antagonizes acetylcholine → Prevents increases in intracellular **cyclic guanosine monophosphate (cGMP)** → Reduces bronchial smooth muscle constriction. * **Advantage over Atropine:** Unlike atropine, ipratropium **does not reduce mucociliary clearance**, making it highly beneficial for patients with respiratory diseases where clearing airway secretions is critical.
Dosing by species
- Adjunctive treatment of RAO, heaves (mild to moderate disease) · 180 micrograms inhaled aerosol · Inhalation · q4-6h · 14 days
- Adjunctive treatment of RAO/heaves (moderate to severe disease) · 90-180 micrograms inhaled via Equine Aeromask or Equine Haler · Inhalation · every 6 hours
- Adjunctive treatment of foals with severe bronchospasm · 2-3 micrograms/kg via aerosol · Inhalation · q6-8h
- As a bronchodilator in rats · one puff into nebulization chamber · Inhalation · twice daily
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Routes of administration
Contraindications
- Hypersensitivity to ipratropium or other atropine derivatives
Adverse effects
- Tracheal or bronchial irritation (coughing)
- Allergic responses
- Mild anticholinergic effects (e.g., dry mouth, tachycardia) in rare cases
Drug interactions
- Anticholinergic drugs · May cause additive antimuscarinic effects
- Beta-adrenergic agonists (e.g., albuterol) · May have additive therapeutic bronchodilatory effects
Monitoring
- Clinical efficacy (improvement in respiratory rate, effort, and lung sounds)
Overdose
Overdosage is unlikely to be a cause for concern. The drug is not well absorbed orally or after inhalation. Oral LD50 values for laboratory animals were greater than 1 gram/kg.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.